Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · February 24, 2022

Capecitabine Maintenance Therapy Plus Best Supportive Care vs Best Supportive Care Alone for Metastatic Nasopharyngeal Carcinoma After Induction Chemotherapy

JAMA Oncology

 

Additional Info

JAMA Oncology
Effect of Capecitabine Maintenance Therapy Plus Best Supportive Care vs Best Supportive Care Alone on Progression-Free Survival Among Patients With Newly Diagnosed Metastatic Nasopharyngeal Carcinoma Who Had Received Induction Chemotherapy: A Phase 3 Randomized Clinical Trial
JAMA Oncol 2022 Feb 17;[EPub Ahead of Print], GY Liu, WZ Li, DS Wang, H Liang, X Lv, YF Ye, C Zhao, LR Ke, SH Lv, N Lu, WX Bei, ZC Cai, X Chen, CX Liang, X Guo, WX Xia, YQ Xiang

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading